--- title: "Insider Buying: Immuneering (NASDAQ:IMRX) Insider Purchases 2,298 Shares of Stock" description: "Immuneering Corporation (NASDAQ:IMRX) insider Brett Matthew Hall purchased 2,298 shares at $4.57 each, totaling $10,501.86, increasing his stake by 0.61% to 376,496 shares valued at $1,720,586.72. The" type: "news" locale: "en" url: "https://longbridge.com/en/news/272886182.md" published_at: "2026-01-16T23:00:43.000Z" --- # Insider Buying: Immuneering (NASDAQ:IMRX) Insider Purchases 2,298 Shares of Stock > Immuneering Corporation (NASDAQ:IMRX) insider Brett Matthew Hall purchased 2,298 shares at $4.57 each, totaling $10,501.86, increasing his stake by 0.61% to 376,496 shares valued at $1,720,586.72. The transaction was disclosed to the SEC. The stock traded down $0.06 to $4.58, with a market cap of $295.73 million. Analysts have mixed ratings, with one strong buy, six buys, and one sell, and an average price target of $16.50. Immuneering is a clinical-stage biopharmaceutical company focused on AI-driven drug development. Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Brett Matthew Hall acquired 2,298 shares of the firm's stock in a transaction that occurred on Thursday, January 15th. The shares were bought at an average price of $4.57 per share, with a total value of $10,501.86. Following the acquisition, the insider directly owned 376,496 shares of the company's stock, valued at $1,720,586.72. The trade was a 0.61% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. ## Immuneering Stock Performance NASDAQ:IMRX traded down $0.06 during trading hours on Friday, reaching $4.58. The stock had a trading volume of 1,571,491 shares, compared to its average volume of 4,332,983. The stock has a 50 day simple moving average of $6.41 and a 200 day simple moving average of $5.77. Immuneering Corporation has a 12-month low of $1.10 and a 12-month high of $10.08. The stock has a market cap of $295.73 million, a P/E ratio of -2.57 and a beta of 0.48. Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01). On average, equities analysts expect that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year. ## Hedge Funds Weigh In On Immuneering A number of institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in shares of Immuneering during the first quarter valued at approximately $32,000. China Universal Asset Management Co. Ltd. bought a new position in Immuneering during the 3rd quarter valued at approximately $35,000. Future Financial Wealth Managment LLC bought a new position in Immuneering during the 3rd quarter valued at approximately $35,000. Kingsview Wealth Management LLC purchased a new position in Immuneering during the second quarter valued at $47,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in Immuneering in the third quarter worth $70,000. 67.65% of the stock is owned by institutional investors. ## Analyst Upgrades and Downgrades IMRX has been the topic of several research reports. Leerink Partnrs upgraded shares of Immuneering to a "strong-buy" rating in a research report on Friday, October 31st. Mizuho set a $12.00 target price on Immuneering in a research note on Wednesday, October 29th. HC Wainwright restated a "buy" rating and set a $11.00 price target on shares of Immuneering in a research report on Tuesday, September 30th. Wall Street Zen cut Immuneering from a "hold" rating to a "sell" rating in a report on Saturday, December 20th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Immuneering in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $16.50. **Check Out Our Latest Research Report on IMRX** ## About Immuneering (Get Free Report) Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need. The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy. ## Featured Stories - Five stocks we like better than Immuneering - NEW LAW: Congress Approves Setup For Digital Dollar? - A month before the crash - How a Family Trust May Be Able To Help Preserve Your Wealth - Why Trump and Musk suddenly care about Fort Knox - If You Keep Cash In A U.S. Bank Account… Read This NOW *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Immuneering Right Now? Before you consider Immuneering, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list. While Immuneering currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [IMRX.US - Immuneering](https://longbridge.com/en/quote/IMRX.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 | Immuneering (NASDAQ: IMRX) CEO Ben Zeskind announced at Oppenheimer’s Healthcare Conference that the company is focused | [Link](https://longbridge.com/en/news/277280010.md) | | Immuneering Director Thomas J. Schall Reports Acquisition of Common Shares | Thomas J. Schall, Director of Immuneering Corporation, has reported the acquisition of Class A common shares of the comp | [Link](https://longbridge.com/en/news/273098166.md) | | Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win | Belite Bio, Inc. reported preliminary fourth-quarter and full-year 2025 results, highlighting a pivotal year for its lea | [Link](https://longbridge.com/en/news/277455527.md) | | Immuneering (NASDAQ:IMRX) Insider Acquires $10,897.90 in Stock | Immuneering Corporation (NASDAQ:IMRX) insider Leah Neufeld purchased 2,626 shares at $4.15 each, totaling $10,897.90, in | [Link](https://longbridge.com/en/news/272726066.md) | | Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data | Immuneering (IMRX) reported promising interim results from its Phase 2a trial of atebimetinib for pancreatic cancer, sho | [Link](https://longbridge.com/en/news/271839962.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.